| 1 | | Completed完成 | | Combination Iron Chelation Therapy 结合铁螯合疗法 |
| Conditions:条件： | | Iron Overload; Thalassemia铁的超负荷;地中海贫血 |
| Intervention:干预： | | Drug: Combination Iron Chelation Therapy药物：结合铁螯合疗法 |
|
| 2二 | | Completed完成 | | Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency 长期铅螯合疗法和进步的肾功能不全 |
| Condition:条件： | | Urologic Disease泌尿系疾病 |
| Intervention:干预： | | Drug: calcium disodium EDTA (edetate calcium disodium)药物：钙的EDTA二钠（ edetate钙钠盐） |
|
| 3三 | | Active, not recruiting积极，不招募 | | Penicillamine Chelation for Children With Lead Poisoning 青霉胺螯合为儿童铅中毒 |
| Conditions:条件： | | Lead Poisoning; Vitamin D Deficiency铅中毒;维生素D缺乏性 |
| Interventions:干预措施： | | Device: d-penicillamine; Drug: placebo装置： D -青霉胺;药物：安慰剂 |
|
| 4四 | | Active, not recruiting积极，不招募 | | An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload 扩展研究的铁螯合疗法与deferasirox在β -地中海贫血患者的输血铁负荷 |
| Condition:条件： | | Transfusional Iron Overload in β-Thalassemia输血铁超载的重型β -地中海贫血 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 5五 | | Active, not recruiting积极，不招募 | | Mercury Chelation to Treat Autism 汞螯合治疗自闭症 |
| Conditions:条件： | | Autism; Asperger’s Disorder; Child Development Disorders, Pervasive自闭症;轻的障碍;儿童发展障碍，无孔不入 |
| Intervention:干预： | | Drug: DMSA药物： dmsa |
|
| 6六 | | Active, not recruiting积极，不招募 | | Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload 铁螯合疗法与deferasirox在β -地中海贫血的主要小儿患者输血铁负荷 |
| Condition:条件： | | Transfusional Iron Overload in β-Thalassemia Major输血铁超载的重型β -地中海贫血的主要 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 7七 | | Active, not recruiting积极，不招募 | | Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload 扩展研究的铁螯合疗法与deferasirox在β -地中海贫血和其他患者罕见的慢性贫血和输血铁负荷 |
| Condition:条件： | | Transfusional Iron Overload in Patients With Chronic Anemia输血铁负荷在治疗慢性贫血 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 8八月 | | Active, not recruiting积极，不招募 | | Iron-Chelating Therapy and Friedreich Ataxia 铁螯合疗法和弗里德赖希共济失调 |
| Condition:条件： | | Friedreich Ataxia弗里德赖希共济失调 |
| Intervention:干预： | | Drug: Iron chelating intervention药物：铁螯合干预 |
|
| 9九 | | Completed完成 | | Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone 螯合疗法的铁负荷与吡哆醛isonicotinoyl腙 |
| Conditions:条件： | | Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload性贫血（铁负荷） ; β -地中海贫血;血液系统疾病; hemoglobinopathies ;地中海贫血;铁负荷 |
| Intervention:干预： | | Drug: chelation therapy药物：螯合疗法 |
|
| 10 10月 | | Completed完成 | | Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload 扩展研究的铁螯合疗法与deferasirox在患者输血铁负荷 |
| Condition:条件： | | Transfusional Iron Overload输血铁负荷 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 11 11月 | | Active, not recruiting积极，不招募 | | Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major 结合螯合治疗与deferiprone和deferoxamine在地中海贫血的主要 |
| Condition:条件： | | Beta-Thalassemia β -地中海贫血 |
| Intervention:干预： | | Drug: deferiprone药物： deferiprone |
|
| 12 12月 | | Completed完成 | | CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients cellcept /铁的研究：铁离子-霉酚酸酯螯合复杂的相互作用，在肾移植受者 |
| Condition:条件： | | End Stage Renal Disease终末期肾脏疾病 |
| Intervention:干预： | | |
|
| 13 13日 | | Active, not recruiting积极，不招募 | | A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload 一项研究，评估疗效和安全性deferasirox在患者输血依赖铁负荷 |
| Condition:条件： | | Transfusion-Dependent Iron Overload输血依赖铁负荷 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 14 14日 | | Active, not recruiting积极，不招募 | | Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload 的疗效和安全性deferasirox在患者输血依赖铁负荷 |
| Condition:条件： | | Transfusion-Dependent Iron Overload输血依赖铁负荷 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 15 15日 | | Completed完成 | | Efficacy Study in Removing Excess Iron From the Heart 疗效研究在消除过剩的铁从心 |
| Conditions:条件： | | Thalassemia Major; Hemosiderosis地中海贫血主要;血 |
| Interventions:干预措施： | | Drug: Ferriprox (deferiprone); Drug: Desferal (deferoxamine)药物： ferriprox （ deferiprone ） ;药物： desferal （ deferoxamine ） |
|
| 16 16日 | | Active, not recruiting积极，不招募 | | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients 研究deferasirox治疗输血铁负荷在骨髓增生异常患者 |
| Conditions:条件： | | Myelodysplastic Syndrome; Iron Overload骨髓增生异常综合征;铁负荷 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 17 17日 | | Active, not recruiting积极，不招募 | | Cardiac Function in Patients With Hereditary Hemochromatosis 患者心功能的遗传性血色病 |
| Condition:条件： | | Hemochromatosis血色病 |
| Intervention:干预： | | |
|
| 18 18日 | | Active, not recruiting积极，不招募 | | A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis 1延长一年研究，以评估安全性，耐受性，药代动力学，及对肝脏铁浓度的deferasirox和deferoxamine在儿童与成年人的镰状细胞病和输血血 |
| Condition:条件： | | Sickle Cell Disease镰状细胞疾病 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 19 19日 | | Active, not recruiting积极，不招募 | | Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis 扩展研究的疗效及安全性deferasirox治疗，在病人与β -地中海贫血和输血血 |
| Condition:条件： | | Beta-Thalassemia Major β -地中海贫血的主要 |
| Intervention:干预： | | Drug: ICL670; deferasirox药物： icl670 ; deferasirox |
|
| 20 20日 | | Completed完成 | | Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis 安全研究tetrathiomolybdate在患者与特发性肺纤维化 |
| Condition:条件： | | Idiopathic Pulmonary Fibrosis特发性肺纤维化 |
| Intervention:干预： | | Drug: Tetrathiomolybdate药物： tetrathiomolybdate |
|
| 21 21日 | | Active, not recruiting积极，不招募 | | Treatment of Lead-Exposed Children Trial 治疗铅接触儿童的审判 |
| Condition:条件： | | Lead Exposure铅暴露 |
| Intervention:干预： | | |
|
| 22 22日 | | Completed完成 | | Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) 羟基脲治疗β -地中海贫血（库的性贫血） |
| Conditions:条件： | | Beta Thalassemia; Hemoglobinopathy试用地中海贫血; hemoglobinopathy |
| Intervention:干预： | | Drug: Hydroxyurea药物：羟基脲 |
|
| 23 23日 | | Completed完成 | | 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia 5 -氮胞苷和苯治疗重症地中海贫血 |
| Condition:条件： | | Beta Thalassemia试用地中海贫血 |
| Intervention:干预： | | Drug: 5-Azacytidine药物： 5 -氮胞苷 |
|
| 24 24日 | | Completed完成 | | Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis 评价皮下desferrioxamine作为输血治疗血色病 |
| Conditions:条件： | | Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload; Hemochromatosis性贫血（铁负荷） ; β -地中海贫血;血液系统疾病; hemoglobinopathies ;地中海贫血;铁的超负荷;血色病 |
| Intervention:干预： | | Drug: deferoxamine药物： deferoxamine |
|
| 25 25日 | | Completed完成 | | Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN) 地中海贫血（库的性贫血）的临床研究网络（ tcrn ） |
| Conditions:条件： | | Anemia, Cooley’s; Beta-Thalassemia; Hematologic Diseases; Thalassemia; Osteoporosis; Iron Overload; Hypertension, Pulmonary贫血，库的; β -地中海贫血;血液系统疾病;地中海贫血;骨质疏松症;铁的超负荷;高血压，肺性 |
| Interventions:干预措施： | | Drug: Deferoxamine; Drug: Deferiprone; Drug: Arginine; Drug: Sildenafil; Drug: Decitabine药物： deferoxamine ;药物： deferiprone ;药物：精氨酸;药物：西地那非;药物：丁化并 |
|
| 26 26日 | | Active, not recruiting积极，不招募 | | Deferoxamine for the Treatment of Hemochromatosis deferoxamine用于治疗血色病 |
| Conditions:条件： | | Diabetes Mellitus; Heart Disease; Hemochromatosis; Thalassemia糖尿病;心脏病;血色病;地中海贫血 |
| Intervention:干预： | | |
|
| 27 27日 | | Completed完成 | | Monoclonal Antibody Therapy in Treating Patients With Leukemia 单克隆抗体疗法在治疗早幼粒细胞白血病 |
| Conditions:条件： | | Lymphoma; Radiation Toxicity淋巴瘤;辐射毒性 |
| Interventions:干预措施： | | Drug: pentetic acid calcium; Drug: yttrium Y 90 daclizumab; Procedure: monoclonal antibody therapy; Procedure: radioimmunotherapy; Procedure: radioprotection药物： pentetic酸钙;药物：钇y 90赛尼哌;程序：单克隆抗体疗法;程序：放射;程序：放射防护 |
|
| 28 28日 | | Completed完成 | | Safety & Efficacy of ICL670 Vs. 安全及疗效icl670队。 Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions deferoxamine在β -地中海贫血患者铁负荷因输血 |
| Condition:条件： | | Beta-Thalassemia β -地中海贫血 |
| Interventions:干预措施： | | Drug: ICL670; Drug: deferoxamine药物： icl670 ;药物： deferoxamine |
|
| 29 29日 | | Completed完成 | | Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias 研究deferasirox在铁负荷由β -地中海贫血无法处理deferoxamine或慢性anemias |
| Conditions:条件： | | Beta-Thalassemia; Myelodysplastic Syndromes; Fanconi Syndrome; Anemia, Diamond-Blackfan; Anemia, Aplastic β -地中海贫血;骨髓增生异常综合征;范可尼综合征;贫血，钻石- blackfan ;贫血，再生障碍性 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 30 30日 | | Completed完成 | | Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions 安全icl670与deferoxamine在镰状细胞疾病患者铁负荷因输血 |
| Condition:条件： | | Anemia, Sickle Cell贫血，镰状细胞 |
| Interventions:干预措施： | | Drug: ICL670; Drug: deferoxamine药物： icl670 ;药物： deferoxamine |
|
| 31 31日 | | Active, not recruiting积极，不招募 | | Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients 研究deferasirox相对皮下deferoxamine在镰状细胞疾病患者 |
| Conditions:条件： | | Sickle Cell Disease; Iron Overload; Hemolytic Anemia镰状细胞病;铁的超负荷;溶血性贫血 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 32 | | Active, not recruiting积极，不招募 | | Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients 研究用于治疗输血铁负荷在骨髓增生异常患者 |
| Conditions:条件： | | Myelodysplastic Syndromes; Iron Overload骨髓增生异常综合征;铁负荷 |
| Intervention:干预： | | Drug: deferasirox药物： deferasirox |
|
| 33 | | Completed完成 | | Chromium Picolinate for the Treatment of Metabolic Syndrome 吡啶羧酸铬，用于治疗代谢综合征 |
| Conditions:条件： | | Metabolic Syndrome X; Prediabetic State; Insulin Resistance; Obesity; Metabolic Diseases代谢X综合征; prediabetic状态;胰岛素抵抗;肥胖;代谢性疾病 |
| Intervention:干预： | | Drug: Chromium picolinate药物：吡啶羧酸铬 |
|
| 34 | | Completed完成 | | A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis 研究长期治疗与deferasirox在患者的β -地中海贫血和输血血 |
| Conditions:条件： | | Beta-Thalassemia; Hemosiderosis β -地中海贫血;血 |
| Intervention:干预： | | Drug: deferasirox药物： deferasirox |
|
| 35 | | Active, not recruiting积极，不招募 | | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload 扩大准入deferasirox病人先天性障碍的红血细胞和慢性铁负荷 |
| Conditions:条件： | | Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia; Myelofibrosis地中海贫血;镰状细胞病;钻石blackfan性贫血;骨髓纤维化 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 36 | | Completed完成 | | Chromium and Insulin Action 铬和胰岛素行动 |
| Condition:条件： | | Type 2 Diabetes 2型糖尿病 |
| Intervention:干预： | | Drug: Chromium Picolinate药物：吡啶羧酸铬 |
|
| 37 | | Completed完成 | | Efficacy and Safety Study of Chromium Picolinate Biotin on Glucose and Cholesterol Control in T2DM 疗效和安全性的研究吡啶羧酸铬 生物素对葡萄糖和胆固醇控制在2型糖尿病 |
| Condition:条件： | | Diabetes Mellitus, Type 2糖尿病， 2型 |
| Intervention:干预： | | Drug: Chromium Picolinate (600 mcg Cr) biotin (2 mg)药物：吡啶羧酸铬（ 600心磁铬） 生物素（ 2毫克） |
|
| 38 | | Completed完成 | | Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-Dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine 评估的可行性，一无细胞百日咳疫苗（ PA ）的给予出生后不久，其次是三剂量疫苗接种，小学与dtpa-hbv-ipv/hib疫苗 |
| Conditions:条件： | | Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Hib Disease白喉;破伤风;百日咳;乙型肝炎;脊髓灰质炎; Hib疾病 |
| Interventions:干预措施： | | Biological: Pertussis vaccine; Biological: DTPa-HBV-IPV/Hib生物：百日咳疫苗;生物： dtpa-hbv-ipv/hib |
|
| 39 | | Completed完成 | | A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM 30天的急性疗效和安全性的研究吡啶羧酸铬 生物素对血糖控制在超重或肥胖的2型糖尿病的科目 |
| Condition:条件： | | Diabetes Mellitus, Type 2糖尿病， 2型 |
| Intervention:干预： | | Drug: Chromium Picolinate (600 mcg Cr 3) biotin (2 mg)药物：吡啶羧酸铬（ 600心磁铬 3 ） 生物素（ 2毫克） |
|
| 40 | | Completed完成 | | Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules 免疫原性和安全的葛兰素史克公司的合并dtpa-hbv-ipv/hib疫苗在印度的婴儿在2差异疫苗接种时间表 |
| Conditions:条件： | | Healthy; Infant健康婴儿 |
| Intervention:干预： | | Biological: DTPa-HBV-IPV/Hib vaccine生物： dtpa-hbv-ipv/hib疫苗 |
|
| 41 | | Completed完成 | | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants 比较的免疫原性和安全2配方的葛兰素史克生物制品' dtpa-hbv-ipv/hib疫苗鉴于在健康婴儿 |
| Conditions:条件： | | Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Haemophilus Influenza Type b Disease白喉;破伤风;百日咳;乙型肝炎;脊髓灰质炎;流感嗜血杆菌B型疾病 |
| Intervention:干预： | | Biological: DTPa-HBV-IPV/Hib vaccine生物： dtpa-hbv-ipv/hib疫苗 |
|
| 42 | | Active, not recruiting积极，不招募 | | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine 安全dtpa-ipv/hib ＆ dtpa-hbv-ipv/hib ，其次是dtpa-ipv/hib疫苗的婴幼儿谁收到的乙肝疫苗 |
| Conditions:条件： | | Healthy; Infant健康婴儿 |
| Intervention:干预： | | Biological: DTPa-HBV-IPV/Hib vaccine生物： dtpa-hbv-ipv/hib疫苗 |
|
| 43 | | Terminated终止 | | Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes 试点审判铬二甲双胍结合2型糖尿病 |
| Condition:条件： | | Type 2 Diabetes 2型糖尿病 |
| Intervention:干预： | | Drug: Chromium Picolinate药物：吡啶羧酸铬 |
|
| 44 | | Active, not recruiting积极，不招募 | | Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients 研究与deferiprone和/或desferrioxamine在铁负荷过重的病人 |
| Condition:条件： | | Hemochromatosis血色病 |
| Interventions:干预措施： | | Drug: Deferiprone (L1); Drug: Desferrioxamine药物： deferiprone （单人房） ;药物： desferrioxamine |
|
| 45 | | Active, not recruiting积极，不招募 | | Iron-Fortified Whole Maize Flour Trial 铁强化整个玉米粉审判 |
| Condition:条件： | | Anaemia贫血 |
| Intervention:干预： | | Drug: NaFeEDTA, Electrolytic Iron药物： nafeedta ，电解铁 |
|
| 46 | | Completed完成 | | Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers 的影响，一个强有力的诱导利福平对药代动力学deferasirox在健康志愿者 |
| Condition:条件： | | Healthy健康 |
| Interventions:干预措施： | | Drug: Deferasirox; Drug: Rifampicin药物： deferasirox ;药物：利福平 |
|
| 47 | | Active, not recruiting积极，不招募 | | Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam 研究探讨deferasirox对药代动力学蓝精灵 |
| Condition:条件： | | Healthy健康 |
| Intervention:干预： | | Drug: Deferasirox药物： deferasirox |
|
| 48 | | Active, not recruiting积极，不招募 | | Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA 核成像人类CSF的流动使用的GA - 67柠檬酸和在- 111 DTPA的 |
| Conditions:条件： | | Central Nervous System Tumors; Brain Tumors中枢神经系统肿瘤;脑肿瘤 |
| Interventions:干预措施： | | Drug: Gallium-67 Citrate; Drug: In-111 DTPA药物：镓-67柠檬酸;药物：在- 111 DTPA的 |
|
| 49 | | Completed完成 | | Effects of Chromium Picolinate on Food Intake 影响吡啶羧酸铬对食物摄入量 |
| Conditions:条件： | | Obesity; Atypical Depression肥胖;非典型抑郁症 |
| Intervention:干预： | | Drug: Chromium Picolinate药物：吡啶羧酸铬 |
|
| 50 | | Completed完成 | | An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients 评估在体内的生物效应diethyldithiocarbamate器（ DTC ）在感染艾滋病毒的患者 |
| Condition:条件： | | HIV Infections受爱滋病病毒感染 |
| Intervention:干预： | | Drug: Ditiocarb sodium药物： ditiocarb钠 |
